10-KPeriod: FY2012

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2012

Filed February 22, 2013For Securities:BSX

Summary

Boston Scientific Corporation's 2012 10-K filing reveals a year of significant restructuring and a focus on key growth areas, despite a net loss driven by substantial goodwill and intangible asset impairment charges totaling $4.492 billion. The company generated $7.249 billion in net sales, a 5% decrease from 2011, primarily due to declines in the Interventional Cardiology and Cardiac Rhythm Management (CRM) segments. However, the Endoscopy and Peripheral Interventions businesses showed growth. Strategic acquisitions in 2012, including Cameron Health (S-ICD system), BridgePoint Medical, Rhythmia Medical, and Vessix Vascular, demonstrate a commitment to expanding the product portfolio in high-growth adjacencies. The company also reported progress on its restructuring initiatives aimed at improving operational efficiency and cost structure. Despite the reported net loss, adjusted net income was $933 million. Key financial metrics like operating cash flow ($1.260 billion) and maintaining investment-grade credit ratings highlight underlying operational strengths. The company's strategy emphasizes strengthening execution, expanding into high-growth areas, driving global expansion, and managing costs effectively.

Financial Highlights

52 data points
Beta

Revenue

$7.25B

67.6% Gross Margin

Net Income

-$4.07B

-56.1% Net Margin

EPS (Diluted)

$-2.89

Total Assets

$17.15B

Cash & Equivalents

$207.00M

Free Cash Flow

$1.05B

Financial Statements
Beta
Revenue$7.25B
Cost of Revenue$2.35B
Gross Profit$4.90B
SG&A Expenses$2.54B
Operating Expenses$8.77B
Operating Income-$3.87B
Interest Expense$261.00M
Net Income-$4.07B
EPS (Basic)$-2.89
EPS (Diluted)$-2.89
Shares Outstanding (Basic)1.41B
Shares Outstanding (Diluted)1.41B

Key Highlights

  • 1Net sales of $7.249 billion in 2012, a 5% decrease from 2011, primarily impacted by declines in Interventional Cardiology and CRM segments.
  • 2Reported a net loss of $4.068 billion, largely due to significant goodwill and intangible asset impairment charges of $4.492 billion.
  • 3Adjusted net income was $933 million, demonstrating underlying profitability despite GAAP charges.
  • 4Completed several strategic acquisitions in 2012, including Cameron Health (S-ICD), BridgePoint Medical, Rhythmia Medical, and Vessix Vascular, to bolster growth areas.
  • 5Achieved $1.260 billion in cash generated from operations, indicating strong cash flow generation.
  • 6Maintained investment-grade credit ratings from Moody's, Fitch, and S&P, reflecting improved financial fundamentals.
  • 7Restructuring initiatives and cost optimization programs are underway to improve operational effectiveness and efficiencies.

Frequently Asked Questions

Boston Scientific's financial performance in 2012 was primarily driven by strategic acquisitions in high-growth areas and ongoing restructuring initiatives. However, net sales decreased by 5% to $7.249 billion, largely due to declines in the Interventional Cardiology and Cardiac Rhythm Management (CRM) segments. A significant factor impacting the reported net loss was the substantial goodwill and intangible asset impairment charges totaling $4.492 billion.

In Interventional Cardiology, the company faced lower market share and declining average selling prices due to competitive launches and pricing pressures, leading to a 13% decrease in net sales. The CRM segment also saw a 9% decline in net sales due to similar pressures and a contraction in the U.S. ICD market. Boston Scientific is addressing these challenges by focusing on new product launches, such as the S-ICD system, and investing in next-generation technologies to regain market share and improve performance.

The substantial goodwill and intangible asset impairment charges of $4.492 billion, primarily in the EMEA and U.S. CRM reporting units, reflect a re-evaluation of future growth prospects and market conditions in those segments. While these charges resulted in a significant net loss, the company's adjusted net income of $933 million indicates that the underlying operations, excluding these non-cash charges, remained profitable.

Boston Scientific's growth strategy is centered on five key imperatives: strengthening execution to grow share, expanding into high-growth adjacencies through strategic acquisitions and R&D, driving global expansion with a focus on emerging markets, funding growth initiatives through cost optimization, and developing key capabilities. The company's recent acquisitions and ongoing investment in R&D underscore this commitment to innovation and market expansion.